Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male Subjects

NCT02994394 is registered in ClinicalTrials.gov with Otsuka Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT02994394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02994394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male Subjects
Lead sponsor
Otsuka Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
January 6, 2017
Completion date
February 28, 2017
Enrollment
84 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adult male